In Brief: USPlabs drops aegeline, bill would allow FSA spending on OTCs, herbal ingredient research draws criticism, P&G supports toothpaste claims
This article was originally published in The Tan Sheet
Executive Summary
USPlabs removes aegeline from formulas; Bill would allow FSA spending on OTCs; Herbal ingredient research draws criticism; P&G supports U.K. toothpaste ad claims; more In Brief.
You may also be interested in...
Nothing Cosmetic About P&G Oral-B Enamel Repair Claims, UK Review Finds
UK's advertising regulator agrees that P&G's TV ads for Oral B Gum and Enamel Repair toothpaste were misleading. P&G argued ad claims that the product could fix enamel and reverse damage were cosmetic, not medicinal, because they only suggested the product could protect gums and promote overall oral health.
Nothing Cosmetic About P&G Oral-B Enamel Repair Claims, UK Review Finds
UK's advertising regulator agrees that P&G's TV ads for Oral B Gum and Enamel Repair toothpaste were misleading. P&G argued ad claims that the product could fix enamel and reverse damage were cosmetic, not medicinal, because they only suggested the product could protect gums and promote overall oral health.
In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill
FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.